Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 50%
Sell 17%
Strong Sell 0%

Bulls say

RxSight Inc. reported a notable gross margin of 71.6%, reflecting a significant increase of 980 basis points year-over-year, surpassing the consensus estimate. The company achieved revenue of $28.5 million from its Light Adjustable Lens (LAL) product, representing a robust growth of 60%, while the Light Delivery Device (LDD) revenue of $10.7 million also showed a steady 7% increase. The positive outlook is supported by expectations of sustained double-digit growth fueled by increased utilization rates and expansion of the LDD installed base, alongside potential margin improvements from favorable product mix dynamics.

Bears say

RxSight Inc. has reported a significant deceleration in light adjustable lens (LAL) utilization growth, which fell to +9% year-over-year in 4Q24, compared to a range of +17%-22% in the previous five quarters, indicating a potential weakening in the company’s market position. Additionally, the U.S. intraocular lens (IOL) market appears to be experiencing stagnation or decline, influenced by increased competition and deteriorating end market conditions, which may adversely affect future sales. The company's lowered earnings per share (EPS) estimates for 2025 and 2026, alongside concerns regarding profitability, limited adoption of their technology, and potential dilution from financing, contribute to an overall negative outlook on RxSight’s stock.

RxSight (RXST) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 12 analysts, RxSight (RXST) has a Hold consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.